Kidney cancer drugs equal in prolonging survival - NewsChannel5.com | Nashville News, Weather & Sports

Kidney cancer drugs equal in prolonging survival

Updated: Aug 22, 2013 10:05 AM
© iStockphoto.com © iStockphoto.com
By Steven Reinberg
HealthDay Reporter

THURSDAY, Aug. 22 (HealthDay News) -- The drug pazopanib (Votrient) works as well as sunitinib (Sutent) for treating advanced kidney cancer, but it has milder side effects, a new study finds.

Although both drugs are approved by the U.S. Food and Drug Administration as first-line treatments for kidney cancer and both boost survival, pazopanib had the edge in improving the quality of life, the researchers reported.

"Kidney cancer has long been considered one of the most difficult-to-treat cancers, and is associated with a poor prognosis when it's metastasized [or spreading]," said lead researcher Dr. Robert Motzer, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City.

Now there are drugs that attack a gene that is responsible for turning kidney cells into cancer cells, he said. "There has been tremendous progress in the treatment of this disease since 2005 with these targeted drugs," Motzer said. "The first of these drugs was sunitinib, which is considered the standard in first-line treatment for kidney cancer."

This new trial was a head-to-head comparison of sunitinib and pazopanib. The researchers found both had a similar safety profile and survival benefit, but there were milder side effects with pazopanib, Motzer said. These included less fatigue and fewer sores on the bottom of the feet, he noted.

"The data also suggest that patients on pazopanib have a better quality of life than patients on sunitinib," Motzer said. Both drugs cost about the same -- about $6,500 a month -- and are covered by Medicare and many private insurers.

"Both these drugs are good options for first-line treatment," Motzer said. "They allow for us to individualize treatment for patients. In my own practice, I have changed my preferred drug from sunitinib over to pazopanib, because most patients appear to have a better quality of life with pazopanib compared with sunitinib."

The trial was paid for by GlaxoSmithKline Pharmaceuticals, the maker of pazopanib.

Dr. Jessica Kreshover, a urologist at North Shore-LIJ's Arthur Smith Institute for Urology in Lake Success, N.Y., said that "this study shows that there is more than one option for first-line therapy for renal [kidney] cancer."

According to Motzer, 65,000 people are diagnosed with kidney cancer each year in the United States. "It's the sixth most common cancer," he said. And because it is often diagnosed late, 30 percent to 50 percent of the patients develop metastasis, he added. "It's one of the top 10 cancer killers," he noted.

The report was published in the Aug. 22 issue of the New England Journal of Medicine.

"We now have a number of treatment options for kidney cancer," said Dr. Len Lichtenfeld, deputy chief medical officer of the American Cancer Society. "The question then becomes how do you make a choice."

Lichtenfeld noted that not only did the study show that the drugs had similar survival benefits and that pazopanib was better at improving patients' quality of life, but also that pazopanib saved health care dollars by cutting the number of doctor visits.

"We need to look at our treatments not only in terms of whether they delay the progression of the cancer or increase overall survival, but also what is the cost to the patient and the medical care system," Lichtenfeld said.

For the study, Motzer's team randomly assigned more than 1,100 patients with advanced kidney cancer to either sunitinib or pazopanib.

The investigators found both drugs fared as well in the length of time they held the cancer at bay and extended life -- about nine months.

The real difference was seen in their side effects. Patients taking pazopanib suffered less fatigue, fewer sores on the hands and feet, and fewer bouts of a blood disease called thrombocytopenia, which can cause bleeding, than patients taking sunitinib, Motzer's group found.

Some patients taking pazopanib, however, had higher levels of an enzyme called alanine aminotransferase -- a sign of potential liver damage -- than those taking sunitinib, the researchers noted.

Most importantly, according to Motzer, patients taking pazopanib rated their quality of life better than patients taking sunitinib.

More information

For more on kidney cancer, visit the American Cancer Society.

Copyright © 2013 HealthDay. All rights reserved.

  • Medical News HeadlinesMedical News HeadlinesMore>>

  • Hope For Lanie: Curing SMA

    Hope For Lanie: Curing SMA

    Thursday, April 17 2014 5:15 PM EDT2014-04-17 21:15:09 GMT
    SMA attacks the body's motor neurons and causes paralysis. There is no cure, but for the first time doctors are studying an experimental therapy that targets more than just symptoms.more>>
    SMA attacks the body's motor neurons and causes paralysis. There is no cure for SMA but for the first time doctors are studying an experimental therapy that targets more than just symptoms, it targets mutated SMN genes, which are responsible for SMA.more>>
  • Washing Lungs & Breathing Better

    Washing Lungs & Breathing Better

    Wednesday, April 16 2014 5:15 PM EDT2014-04-16 21:15:09 GMT
    Imagine not being able to breathe without struggling: every breath you take is work; every breath you take could be your last. That was the case for one man who became dependent on an oxygen tank to stay alive.more>>
    Imagine not being able to breathe without struggling: every breath you take is work; every breath you take could be your last. That was the case for one man who became dependent on an oxygen tank to stay alive.more>>
  • Ocular Melanoma: Saving Lives, Saving Eyes

    Ocular Melanoma: Saving Lives, Saving Eyes

    Friday, April 11 2014 5:15 PM EDT2014-04-11 21:15:07 GMT
    Ocular melanoma, also called uveal melanoma, is a rare type of melanoma that targets the eye. It can be a deadly if it isn't spotted early enough. Now, there's a way to treat patients that's saving lives and saving eyes.more>>
    Ocular melanoma, also called uveal melanoma, is a type of melanoma that targets the eye. It affects about 2,000 people a year in the United States. Although rare – it can be a deadly if it isn't spotted early enough. Now, there's a way to treat patients that's saving lives and saving eyes.more>>
  • Memory Palace: Coping With Chemo Brain

    Memory Palace: Coping With Chemo Brain

    Thursday, April 10 2014 5:15 PM EDT2014-04-10 21:15:09 GMT
    More than 13 million Americans are living with some form of cancer. Harsh treatments like chemo and radiation save lives, but they will also change lives. Now, many cancer survivors are learning how to cope with chemo brain.more>>
    More than 13 million Americans are living with some form of cancer. Harsh treatments like chemo and radiation save lives, but they will also change lives. Now, many cancer survivors are learning how to cope with chemo brain.more>>
  • Pedaling For A Cure

    Pedaling For A Cure

    Wednesday, April 9 2014 5:15 PM EDT2014-04-09 21:15:09 GMT
    Five years ago, Leslie Trudeau's world came crashing down. At just 22 years old, her son Taylor lost his battle with leukemia. That's why Trudeau is pedaling for a cure.more>>
    Five years ago, Leslie Trudeau's world came crashing down. At just 22 years old, her son Taylor lost his battle with leukemia. That's why Trudeau is pedaling for a cure.more>>
  • Bringing Hearts Back To Life: New Improved Defibrillator

    Bringing Hearts Back To Life: New Improved Defibrillator

    Tuesday, April 8 2014 5:15 PM EDT2014-04-08 21:15:13 GMT
    CPR and a portable defibrillator helped keep Eric Robinson alive after he went into cardiac arrest. And now a newly FDA approved Biotronik implantable cardiac defibrillator, or ICD, constantly monitors his heart.more>>
    A year ago, while jamming with his son's band, Eric Robinson went into cardiac arrest. CPR and a portable defibrillator helped keep Robinson alive. And now a newly FDA approved Biotronik implantable cardiac defibrillator, or ICD, constantly monitors his heart.more>>
  • Helping High Risk Hearts

    Helping High Risk Hearts

    Monday, April 7 2014 5:15 PM EDT2014-04-07 21:15:09 GMT
    Ironing is not exactly Barbara Roy's favorite activity, but it's something she's glad she can do again. Her doctor diagnosed her with severe aortic stenosis.more>>
    Ironing is not exactly Barbara Roy's favorite activity, but it's something she's glad she can do again. Her doctor diagnosed her with severe aortic stenosis.more>>
  • Hernias In Newborns: Lincoln's Story

    Hernias In Newborns: Lincoln's Story

    Friday, April 4 2014 5:15 PM EDT2014-04-04 21:15:07 GMT
    Congenital diaphragmatic hernias occur in about one in every 2,000 births. They can be deadly, but now doctors are using a more aggressive treatment approach.more>>
    Congenital diaphragmatic hernias occur in about one in every 2,000 births. They can be deadly, but now doctors are using a more aggressive treatment approach.more>>
  • Predicting Bad Hearts

    Predicting Bad Hearts

    Thursday, April 3 2014 5:15 PM EDT2014-04-03 21:15:09 GMT
    Every year, more than 700,000 Americans have a heart attack. Now, researchers at Baylor Research Institute at Dallas have uncovered a biomarker that may help them spot the disease sooner.more>>
    Every year, more than 700,000 Americans have a heart attack. And 600,000 die of heart disease. Now, researchers at Baylor Research Institute at Dallas have uncovered a biomarker that may help them spot the disease sooner; and they did it by pure accident.more>>
  • Giving Shannon A Voice Of Her Own

    Giving Shannon A Voice Of Her Own

    Wednesday, April 2 2014 5:15 PM EDT2014-04-02 21:15:05 GMT
    More than half a million children under age 15 has a severe communication disorder impairing their ability to speak or communicate with others. Now, advances in technology are giving them a voice—some for the first time.more>>
    More than half a million children under age 15 has a severe communication disorder impairing their ability to speak or communicate with others. Now, advances in technology are giving them a voice—some for the first time.more>>
*DISCLAIMER*: The information contained in or provided through this site section is intended for general consumer understanding and education only and is not intended to be and is not a substitute for professional advice. Use of this site section and any information contained on or provided through this site section is at your own risk and any information contained on or provided through this site section is provided on an "as is" basis without any representations or warranties.
Powered by WorldNow
Powered by WorldNow
All content © Copyright 2000 - 2014 NewsChannel 5 (WTVF-TV) and WorldNow. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.